Literature DB >> 19252424

Protective effects of natural rotavirus infection.

F Raúl Velázquez1.   

Abstract

Rotavirus is a ubiquitous infection that is the leading cause of severe diarrhea worldwide. Severe infections are most commonly observed in the first 2 years of life. Rotavirus-induced diarrhea is associated with substantial morbidity and mortality rates and socioeconomic costs with adverse outcomes particularly prevalent in developing countries. The natural history of rotavirus infection can provide guidance for the development and optimization of an effective vaccine. Epidemiologic studies have demonstrated that children who acquire natural rotavirus infections develop immunity to subsequent infections, with the protective effect increasing with each natural infection. Natural infections also decrease the severity of any subsequent rotavirus infections. Notably, asymptomatic infections provide protection similar to that induced by symptomatic infections. Data also suggest that the antibody response to natural infection is heterotypic, and therefore may provide protection against multiple serotypes. These data suggest that the development of a vaccine that produces asymptomatic infection at an optimal time point may provide effective immunity. An effective vaccine should mimic protection provided by natural infection and provide protection against the most common rotavirus serotypes (ie, G1, G2, G3, G4, G9) and be able to decrease disease severity, reduce hospitalizations, and decrease disease-related costs.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19252424     DOI: 10.1097/INF.0b013e3181967c03

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  15 in total

Review 1.  Rotavirus vaccine RIX4414 (Rotarix™): a pharmacoeconomic review of its use in the prevention of rotavirus gastroenteritis in developing countries.

Authors:  Greg L Plosker
Journal:  Pharmacoeconomics       Date:  2011-11       Impact factor: 4.981

Review 2.  Rotavirus diversity and evolution in the post-vaccine world.

Authors:  John T Patton
Journal:  Discov Med       Date:  2012-01       Impact factor: 2.970

Review 3.  Immune responses to rotavirus infection and vaccination and associated correlates of protection.

Authors:  Ulrich Desselberger; Hans-Iko Huppertz
Journal:  J Infect Dis       Date:  2011-01-15       Impact factor: 5.226

4.  Wading Into the Morass: Natural Immunity to Enteropathogens.

Authors:  Benjamin A Lopman; Julia M Baker
Journal:  J Infect Dis       Date:  2020-11-09       Impact factor: 5.226

Review 5.  Pentavalent rotavirus vaccine (RotaTeq): a review of its use in the prevention of rotavirus gastroenteritis in Europe.

Authors:  Greg L Plosker
Journal:  Drugs       Date:  2010-06-18       Impact factor: 9.546

Review 6.  Immunity to enteric viruses.

Authors:  Ainsley Lockhart; Daniel Mucida; Roham Parsa
Journal:  Immunity       Date:  2022-05-10       Impact factor: 43.474

7.  Pharmacoeconomic spotlight on rotavirus vaccine RIX4414 (Rotarix™) in developed countries.

Authors:  Greg L Plosker
Journal:  Drugs R D       Date:  2012-12-01

Review 8.  Rotavirus vaccine RIX4414 (Rotarix™): a pharmacoeconomic review of its use in the prevention of rotavirus gastroenteritis in developed countries.

Authors:  Greg L Plosker
Journal:  Pharmacoeconomics       Date:  2011-05       Impact factor: 4.558

Review 9.  Pharmacoeconomic spotlight on rotavirus vaccine RIX4414 (Rotarix™) in the prevention of rotavirus gastroenteritis in developing countries.

Authors:  Greg L Plosker
Journal:  Paediatr Drugs       Date:  2012-12-01       Impact factor: 3.930

10.  Impact of rotavirus vaccination on hospitalisations in Belgium: comparing model predictions with observed data.

Authors:  Baudouin Standaert; Jorge A Gomez; Marc Raes; Serge Debrus; F Raúl Velázquez; Maarten J Postma
Journal:  PLoS One       Date:  2013-01-18       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.